Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.37 |
| ▸ | HSP90AA1 known ✓ | P07900 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4542347 | 1.00 | GAA (0.37) | GAAPOLBTRPM8IDO1HSP90AA1 | |
| SCHEMBL2868301 | 0.98 | GAA (0.38) | GAAPOLBTRPM8IDO1HSP90AA1 | |
| SCHEMBL3276196 | 0.98 | GAA (0.38) | GAAPOLBTRPM8IDO1HSP90AA1 | |
| SCHEMBL6568409 | 0.96 | GAA (0.39) | GAAPOLBTRPM8IDO1HSP90AA1 | |
| Hydrochloric Acid SCHEMBL4248410 | 0.82 | HSP90AA1 (0.40) | GAAPOLBTRPM8HSP90AA1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL175377 | 0.78 | POLB (0.37) | GAAPOLBTRPM8IDO1HSP90AA1 | |
| Hydrochloric Acid SCHEMBL4542337 | 0.78 | POLB (0.37) | GAAPOLBTRPM8IDO1HSP90AA1 | |
| Iodide SCHEMBL2464728 | 0.78 | POLB (0.37) | GAAPOLBTRPM8IDO1HSP90AA1 | |
| Bromide SCHEMBL2467102 | 0.78 | POLB (0.37) | GAAPOLBTRPM8IDO1HSP90AA1 | |
| Hydrochloric Acid SCHEMBL2064723 | 0.78 | POLB (0.37) | GAAPOLBTRPM8IDO1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6303837-B1 | CYCLOOLEFINATION BY METATHESIS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-10-16 | — | — | US | claimed |
| US-8356527-B2 | Inspection apparatus having an insertion tube with dispersed healing agent | GE INSPECTION TECHNOLOGIES, LP (US) | 2013-01-22 | — | — | US | disclosed |
| US-20100036321-A1 | INSPECTION APPARATUS HAVING AN INSERTION TUBE WITH DISPERSED HEALING AGENT | GE INSPECTION TECHNOLOGIES, LP | 2010-02-11 | — | — | US | disclosed |
| US-7470750-B2 | Method for the degradation of nitrile rubber by metathesis in the presence of ruthenium- or osmium-based catalysts | LANXESS DEUTSCHLAND GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-20070049700-A1 | Method for the degradation of nitrile rubber by metathesis in the presence of ruthenium- or osmium-based catalysts | LANXESS DEUTSCHLAND GMBH (DE) | 2007-03-01 | — | — | US | disclosed |
| EP-1754700-A2 | Synthesis of oligoketides | Kosan Biosciences, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-7084222-B2 | Ruthenium complexes, process for preparation thereof, and processes for producing open-ring polymer of cycloolefins and hydrogenation products thereof by using the complex as catalyst | ZEON CORPORATION (JP) | 2006-08-01 | — | — | US | disclosed |
| US-20060148779-A1 | Monocyclic anilide spirohydantoin cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2006-07-06 | — | — | US | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| US-7022825-B2 | Polyketides and antibiotics | KOSAN BIOSCIENCES, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20020077428-A1 | PROCESS FOR THE SYNTHESIS OF HYDROXYL-END GROUP FUNCTIONALIZED POLYBUTADIENES | BAYER CORPORATION | 2002-06-20 | — | — | US | disclosed |
| US-6391978-B1 | MIXTURE CONTAINING CHAIN TRANSFER AGENT AND POLYMERIZATION CATALYSTS | BAYER CORPORATION | 2002-05-21 | — | — | US | disclosed |
| EP-1144375-A2 | SYNTHESIS OF OLIGOKETIDES | Kosan Biosciences (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000044717-A9 | SYNTHESIS OF OLIGOKETIDES | — | 2001-08-23 | — | — | WO | disclosed |
| WO-2001048046-A1 | HYDROPHOBIC LIGHT STABLE POLYURETHANE ELASTOMER WITH IMPROVED MECHANICAL PROPERTIES | BAYER CORPORATION (US) | 2001-07-05 | — | — | WO | disclosed |
| US-6211324-B1 | CHAIN EXTENSION | BAYER CORPORATION | 2001-04-03 | — | — | US | disclosed |
| US-6166166-A | Composition and process for preparation of thermoplastic polyurethanes (TPU based on a polybutadiene soft segment) | BAYER CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000044717-A2 | SYNTHESIS OF OLIGOKETIDES | KOSAN BIOSCIENCES, INC. (US) | 2000-08-03 | — | — | WO | disclosed |
| EP-0982332-A1 | Composition and process for preparation of thermoplastic polyurethanes (tpu based on a polybutadiene soft segment) | Bayer Corporation (US) | 2000-03-01 | — | — | EP | disclosed |
| US-5990340-A | Polyurethane polyolefins and prepolymers based on hydroxy functional polybutadiene | BAYER CORPORATION (US) | 1999-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148779-A1 | Monocyclic anilide spirohydantoin cgrp receptor antagonists | CALCRL, CALCR, CCKAR | GAA 3008/4885HSP90AA1 2741/4885POLB 4826/4885 |
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | GAA 1120/4885HSP90AA1 3310/4885POLB 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.